Evidence map›Paper›PMID 40515880›Full record

ArticleInsights into imaging2025

Contrast-enhanced mammography for breast cancer detection and diagnosis with high concentration iodinated contrast medium.

Federica Pediconi, Annarita Speranza, Giuliana Moffa, Roberto Maroncelli, Sara Coppola, Francesca Galati, Claudia Bernardi, Giacomo Maccagno, Dominga Pugliese, Carlo Catalano and 2 more

Abstract read
In one paragraph

Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Federica PediconiDepartment of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Policlinico "Umberto I", Rome, Italy.
Annarita SperanzaDepartment of Surgical and Medical Sciences and Translational Medicine, Sapienza, University of Rome, Sant'Andrea University Hospital, Rome, Italy.
Giuliana MoffaDepartment of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Policlinico "Umberto I", Rome, Italy.
Roberto MaroncelliDepartment of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Policlinico "Umberto I", Rome, Italy. roberto.maroncelli@uniroma1.it.ORCID http://orcid.org/0009-0006-6626-2478
Sara CoppolaDepartment of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Policlinico "Umberto I", Rome, Italy.
Francesca GalatiDepartment of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Policlinico "Umberto I", Rome, Italy.
Claudia BernardiDepartment of Surgical and Medical Sciences and Translational Medicine, Sapienza, University of Rome, Sant'Andrea University Hospital, Rome, Italy.
Giacomo MaccagnoDepartment of Surgical and Medical Sciences and Translational Medicine, Sapienza, University of Rome, Sant'Andrea University Hospital, Rome, Italy.
Dominga PuglieseDepartment of Surgical and Medical Sciences and Translational Medicine, Sapienza, University of Rome, Sant'Andrea University Hospital, Rome, Italy.
Carlo CatalanoDepartment of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Policlinico "Umberto I", Rome, Italy.
Andrea LaghiDepartment of Surgical and Medical Sciences and Translational Medicine, Sapienza, University of Rome, Sant'Andrea University Hospital, Rome, Italy.
Veronica RizzoDepartment of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Policlinico "Umberto I", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe assessed the diagnostic performance of contrast-enhanced mammography (CEM) using a high-concentration iodinated contrast medium (HCCM, 400 mgI/mL) to determine whether the reduced iodine dose and increased iodine delivery rate (IDR) achieved might offer a more sustainable alternative to CEM performed with lower iodine concentrations.

methodsThis two-center retrospective study included 205 patients who underwent CEM between March 2021 and February 2022. Patients were injected with HCCM at 1.0 mL/kg bodyweight at an IDR of 1.2 gL/s. Standard cranio-caudal and mediolateral-oblique views were acquired. Images were reviewed independently by two experienced radiologists who were blinded to patient clinical and imaging information. Diagnostic performance, including sensitivity, specificity, and accuracy, was assessed based on histological or long-term imaging follow-up as the reference standard.

resultsAmong the 205 patients, 149 (72.7%) had malignant lesions, and 56 (27.3%) had benign findings. The sensitivity and specificity of CEM were 96-97% and 84-87.5%, respectively, with an overall accuracy of 93-95%. The IDR achieved with HCCM resulted in excellent contrast enhancement, particularly in patients with aggressive malignancies. ROC analysis confirmed the good diagnostic performance, with AUC values of 0.90-0.92. Compared to conventional mammography and ultrasound, CEM demonstrated significantly higher diagnostic accuracy, especially in patients with dense breast tissue.

conclusionsCEM with HCCM provides excellent diagnostic performance, achieving high sensitivity and specificity while allowing for a reduced iodine dose and increased IDR. This approach may offer a more sustainable alternative to conventional contrast media without compromising diagnostic accuracy, particularly for the detection and characterization of aggressive breast lesions. CRITICAL RELEVANCE STATEMENT: This study demonstrates that reducing the volume of injected contrast media while increasing iodine concentration maintains the diagnostic benefits of CEM, further supporting its potential to improve early cancer detection, thereby advancing clinical radiology practices and optimizing screening strategies for women with dense breasts. KEY POINTS: Currently, CEM protocols utilize a variety of iodine concentrations and flow rates. CEM with high-concentration contrast (400 mgI/mL) achieved 96% sensitivity and 87.5% specificity. High-concentration contrast in CEM improves early detection of aggressive breast cancers.

Indexed as

Breast cancerCEMDiagnostic performanceHigh iodine concentrationIodinated contrast media

Identifiers

PMID40515880
PMCPMC12167179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.